$5.70 $0.01 (0.2%)

04:00 PM EST on 12/06/19

Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Current Price $5.70 Mkt Cap $478.0M
Open $5.71 P/E Ratio 0.00
Prev. Close $5.69 Div. (Yield) $0.00 (0.0%)
Daily Range $5.64 - $5.85 Volume 848,149
52-Wk Range $2.60 - $12.42 Avg. Daily Vol. 1,040,506

Caps

How do you think NASDAQ:DVAX will perform against the market?

Add Stock to CAPS Watchlist

All Players

197 Outperform
15 Underperform
 

All-Star Players

27 Outperform
8 Underperform
 

Wall Street

6 Outperform
0 Underperform
 

Top NASDAQ:DVAX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Patastic (24.09)
Submitted August 09, 2017

Heplisav Approval almost a lock. SD-101 shows great promise in combination with Keytruda (100% ORR). New lung cancer inhalable TLR agonist in combo with anti PD-1 going into trials this quarter. Partnership with AstraZeneca on a cure for… More

zzlangerhans (99.72)
Submitted November 14, 2016

The zzporte portfolio ate a large helping of dirt today with the announcement of the CRL for Heplisav. The CRL wasn't an enormous surprise, given the tortuous history of Heplisav and the cancellation of the Ad Comm. I probably wouldn't have bought… More

NASDAQ:DVAX VS S&P 500 (SPY)

Fools bullish on NASDAQ:DVAX are also bullish on:

Fools bearish on NASDAQ:DVAX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about DVAX.

Recs

0
Member Avatar TMFGBudwell (22.21) Submitted: 12/18/2017 4:17:46 AM : Outperform Start Price: $19.40 NASDAQ:DVAX Score: -88.18

Undervalued from a long-term growth perspective.

Recs

1
Member Avatar Patastic (24.09) Submitted: 8/9/2017 4:52:28 PM : Outperform Start Price: $16.25 NASDAQ:DVAX Score: -92.31

Heplisav Approval almost a lock. SD-101 shows great promise in combination with Keytruda (100% ORR). New lung cancer inhalable TLR agonist in combo with anti PD-1 going into trials this quarter. Partnership with AstraZeneca on a cure for asthma...Holy cow. I'm in long on this one.

Recs

0
Member Avatar rocknrook (53.00) Submitted: 1/19/2017 12:20:50 PM : Outperform Start Price: $4.30 NASDAQ:DVAX Score: -7.12

I think management is finally getting their act together on approval process. Hep drug should approve soon & other potentials in the pipeline. Once Hep comes through, I expect a large pop in value.

Leaderboard

Find the members with the highest scoring picks in DVAX.

Score Leader

MarkBiotech

MarkBiotech (< 20) Score: +296.26

The Score Leader is the player with the highest score across all their picks in DVAX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mavimadero 42.68 10/9/2006 Underperform 3W $72.90 -92.22% +147.81% +240.02 0 Comment
hawkider < 20 12/8/2006 Underperform 3Y $95.20 -94.04% +136.84% +230.88 1 Comment
HondurasAlan 72.37 1/8/2007 Underperform 3W $61.40 -90.76% +136.57% +227.33 0 Comment
Turkmenbashi 53.33 1/8/2007 Underperform NS $59.70 -90.49% +136.74% +227.24 0 Comment
dozer963 37.06 3/18/2008 Underperform NS $23.00 -75.33% +149.82% +225.14 0 Comment
cthomas1017 98.93 12/7/2012 Underperform 5Y $26.05 -78.21% +120.90% +199.12 0 Comment
rqtect < 20 2/27/2013 Underperform 3W $21.00 -72.98% +110.05% +183.03 0 Comment
rknapton 80.80 8/7/2013 Underperform 5Y $13.50 -57.96% +86.09% +144.06 1 Comment
hicksjmu567 80.54 10/30/2013 Underperform 3Y $12.50 -54.60% +78.32% +132.92 0 Comment
brogers146 70.39 10/28/2013 Underperform 5Y $12.30 -53.86% +79.00% +132.87 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DVAX.